Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 19/20 | 0.60 |
| ▸ | CHRM2 | P08172 | 12/20 | 0.60 |
| ▸ | CHRM1 | P11229 | 10/20 | 0.57 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.57 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.57 |
| ▸ | TSPO | P30536 | 1/20 | 0.57 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.57 |
| ▸ | HRH1 | P35367 | 1/20 | 0.57 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.57 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.57 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14278854 | 1.00 | CHRM3 (0.60) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL16742011 | 1.00 | CHRM3 (0.60) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL14472825 | 1.00 | CHRM3 (0.60) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL4886984 | 0.85 | CHRM3 (0.60) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL4886957 | 0.85 | CHRM3 (0.60) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL4886970 | 0.85 | CHRM3 (0.60) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL15926494 | 0.82 | CHRM3 (0.69) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL14278853 | 0.82 | CHRM3 (0.69) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL14304865 | 0.82 | CHRM3 (0.69) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL15186127 | 0.82 | CHRM3 (0.69) | CHRM3CHRM2CHRM1CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10954211-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2021-03-23 | — | — | US | disclosed |
| US-20190330187-A1 | Chemical Compounds | ASTRAZENECA UK LIMITED (GB) | 2019-10-31 | — | — | US | disclosed |
| EP-2897588-B1 | AN INHALABLE MEDICAMENT | TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D INC (US) | 2019-07-17 | — | — | EP | disclosed |
| US-10336725-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2019-07-02 | — | — | US | disclosed |
| US-20180162838-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2018-06-14 | — | — | US | disclosed |
| EP-3119752-B1 | 3,4-DIAMINO-6-CHLOROPYRAZINE-2-CARBOXAMIDE COMPOUNDS FOR THE TREATMENT OF ENAC MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2018-05-16 | — | — | EP | disclosed |
| US-9873678-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2018-01-23 | — | — | US | disclosed |
| US-9707295-B2 | Inhalable medicament | TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC. (US) | 2017-07-18 | — | — | US | disclosed |
| US-20170107195-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2017-04-20 | — | — | US | disclosed |
| EP-3119752-A1 | CHEMICAL COMPOUNDS | Astrazeneca AB (SE) | 2017-01-25 | — | — | EP | disclosed |
| US-20100099867-A1 | PROCESS FOR THE PREPARATION OF TIOTROPIUM BROMIDE | SICOR, INC. (US) | 2010-04-22 | — | — | US | disclosed |
| US-20100099867-A1 | PROCESS FOR THE PREPARATION OF TIOTROPIUM BROMIDE | SICOR, INC. (US) | 2010-04-22 | — | — | US | disclosed |
| US-7662963-B2 | Process for the preparation of tiotropium bromide | SICOR INC. (US) | 2010-02-16 | — | — | US | disclosed |
| US-7662963-B2 | Process for the preparation of tiotropium bromide | SICOR INC. (US) | 2010-02-16 | — | — | US | disclosed |
| US-20090247747-A1 | PROCESS FOR THE PREPARATION OF TIOTROPIUM BROMIDE | SICOR, INC. (US) | 2009-10-01 | — | — | US | disclosed |
| US-20090247747-A1 | PROCESS FOR THE PREPARATION OF TIOTROPIUM BROMIDE | SICOR, INC. (US) | 2009-10-01 | — | — | US | disclosed |
| US-20080051582-A1 | Process for the preparation of tiotropium bromide | SICOR INC. (US) | 2008-02-28 | — | — | US | disclosed |
| US-20080051582-A1 | Process for the preparation of tiotropium bromide | SICOR INC. (US) | 2008-02-28 | — | — | US | disclosed |
| US-7321039-B2 | Industrial process for preparing tropenol | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2008-01-22 | — | — | US | disclosed |
| WO-2008008376-A2 | SCOPINE SALTS AND THEIR USE IN PROCESSES FOR THE PREPARATION OF N-DEMETHYL-TIOTROPIUM AND TIOTROPIUM BROMIDE | SICOR INC. (US) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170107195-A1 | Chemical Compounds | CFTR, SCNN1B, SCNN1A | CHRM3 167/4885CHRM2 910/4885CHRM1 953/4885 |
| US-10336725-B2 | Chemical compounds | CFTR, SCNN1B, SCNN1A | CHRM3 167/4885CHRM2 910/4885CHRM1 953/4885 |
| US-20180162838-A1 | Chemical Compounds | CFTR, SCNN1B, SCNN1A | CHRM3 167/4885CHRM2 910/4885CHRM1 953/4885 |
| US-10954211-B2 | Chemical compounds | CFTR, SCNN1B, SCNN1A | CHRM3 167/4885CHRM2 910/4885CHRM1 953/4885 |
| US-20080051582-A1 | Process for the preparation of tiotropium bromide | ADRA2B, ADRA1B, CYP3A5 | CHRM3 12/4885CHRM2 56/4885CHRM1 158/4885 |
| US-20090247747-A1 | PROCESS FOR THE PREPARATION OF TIOTROPIUM BROMIDE | ADRA2B, ADRA1B, CYP3A5 | CHRM3 12/4885CHRM2 56/4885CHRM1 158/4885 |
| US-20100099867-A1 | PROCESS FOR THE PREPARATION OF TIOTROPIUM BROMIDE | ADRA2B, ADRA1B, CYP3A5 | CHRM3 12/4885CHRM2 56/4885CHRM1 158/4885 |
| US-20190330187-A1 | Chemical Compounds | CFTR, SCNN1B, SCNN1A | CHRM3 167/4885CHRM2 910/4885CHRM1 953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.